29
Participants
Start Date
October 31, 2013
Primary Completion Date
June 1, 2016
Study Completion Date
March 23, 2017
IXAZOMIB
Each 28-day treatment cycle will include oral administration of IXAZOMIB on Days 1, 8, and 15 followed by a rest period of 13 days.
Boston
New York
Nashville
Houston
Ghent
Leuven
Wilrijk
Montreal
London
Manchester
Newcastle upon Tyne
Plymouth
Southampton
Sutton
Lead Sponsor
Millennium Pharmaceuticals, Inc.
INDUSTRY